| Diversified Consumer Services Industry | Consumer Discretionary Sector | Iris Bincovich CEO | ASX Exchange | Q9034Z105 CUSIP |
| CA Country | 11 Employees | 6 Oct 2015 Last Dividend | - Last Split | - IPO Date |
InnoCan Pharma Corporation is a pioneering pharmaceutical technology company with a keen focus on developing innovative drug delivery platforms that merge cannabidiol (CBD) with other pharmaceutical ingredients. The company's operations span across the United States, Canada, Europe, and other international markets. It is structured into two main segments: Pharmaceuticals and Consumer Wellness. At its core, InnoCan Pharma is committed to advancing the research and development of CBD loaded exosomes and the LPT CBD-loaded liposome platform. These platforms are designed to ensure precise dosing and the sustained, controlled release of CBD into the bloodstream, targeting conditions such as epilepsy and pain management. Established in 2018 and based in Calgary, Canada, InnoCan Pharma is at the forefront of integrating CBD into pharmaceutical and topical treatment products, aiming to bridge the gap between the health benefits of CBD and the needs of patients worldwide.